Xenon Pharmaceuticals (XENE) Stock Forecast, Price & News

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Xenon Pharmaceuticals stock.
View analyst ratings for Xenon Pharmaceuticals or view top-rated stocks.

7 brokerages have issued 12 month price objectives for Xenon Pharmaceuticals' shares. Their XENE stock forecasts range from $40.00 to $55.00. On average, they anticipate Xenon Pharmaceuticals' share price to reach $45.33 in the next twelve months. This suggests a possible upside of 17.8% from the stock's current price.
View analysts' price targets for Xenon Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Xenon Pharmaceuticals' stock was trading at $31.24 at the beginning of 2022. Since then, XENE shares have increased by 23.1% and is now trading at $38.47.
View the best growth stocks for 2022 here.

Xenon Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our earnings forecast for Xenon Pharmaceuticals.

Xenon Pharmaceuticals will be holding an earnings conference call on Tuesday, August 9th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) issued its quarterly earnings results on Tuesday, May, 10th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.03. The biopharmaceutical company had revenue of $8.77 million for the quarter, compared to analyst estimates of $9.22 million. Xenon Pharmaceuticals had a negative net margin of 360.80% and a negative trailing twelve-month return on equity of 20.94%. During the same period in the previous year, the business earned ($0.42) earnings per share.

Based on aggregate information from My MarketBeat watchlists, some companies that other Xenon Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Corbus Pharmaceuticals (CRBP), Nektar Therapeutics (NKTR), TG Therapeutics (TGTX), Viking Therapeutics (vktx), Sangamo Therapeutics (SGMO), Arbutus Biopharma (ABUS), OPKO Health (OPK) and Spectrum Pharmaceuticals (SPPI).

Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE."

Xenon Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Candriam S.C.A. (1.63%), Silverarc Capital Management LLC (0.44%), Russell Investments Group Ltd. (0.20%), Integral Health Asset Management LLC (0.18%), Scotia Capital Inc. (0.07%) and Tekla Capital Management LLC (0.06%). Company insiders that own Xenon Pharmaceuticals stock include Christopher John Kenney, Frank A Holler, James R Empfield, Mohammad Azab, Seggern Christopher Von, Sherrington Robin and Simon N Pimstone.
View institutional ownership trends for Xenon Pharmaceuticals.

Shares of XENE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of XENE stock can currently be purchased for approximately $38.47.

Xenon Pharmaceuticals (NASDAQ:XENE) has a market capitalization of $2.04 billion and generates $18.44 million in revenue each year. The biopharmaceutical company earns $-78,880,000.00 in net income (profit) each year or ($1.79) on an earnings per share basis.

Xenon Pharmaceuticals employs 149 workers across the globe.

Xenon Pharmaceuticals' mailing address is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. The official website for Xenon Pharmaceuticals is www.xenon-pharma.com. The biopharmaceutical company can be reached via phone at (604) 484-3300, via email at investors@xenon-pharma.com, or via fax at 604-484-3450.